Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

Fig. 4

a NMA reporting RR for primary outcome in patients with T2DM and CKD. b NMA reporting RR for major adverse cardiovascular events in patients with T2DM and CKD. c NMA reporting RR for hospitalization for heart failure in patients with T2DM and CKD. d NMA reporting RR for nonfatal stroke in patients with T2DM and CKD. e NMA reporting RR for adverse events in patients with T2DM and CKD. f NMA reporting RR for serious adverse events in patients with T2DM and CKD. g NMA reporting RR for serious hyperkalemia in patients with T2DM and CKD

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us